

effects on Kaposi's sarcoma in the absence of a CG-like molecule in mice?

Of potentially more importance, the biological function of hCG is mediated by the α hCG/ β hCG dimer and not by the free β hCG subunit, but the same function and receptors are being proposed for hCG β as for hCG by Lunardi-Iskandar *et al.* This contradiction could be clarified by conventional radioreceptor assays or by direct demonstration of LH/hCG-receptor gene expression, but not by an immunohistochemical demonstration of receptors with a polyclonal antiserum against the ligand, as performed by Lunardi-Iskandar *et al.* The hormonal profiles of pregnancy sera differ vastly from sera of non-pregnant humans and mice, not only with respect to hCG. The investigators should have included some conclusive specificity controls such as immunoneutralization by monoclonal antibodies against both hCG and its subunits^{9,10}. The same applies to the crude hCG preparations used in their bioassays, especially as they did not rely on highly purified material (for example, hCG CR-127, 14,900 IU per mg), which is made available by their own research institution, NIH. Whether it is really CG, or even more surprisingly free β hCG, which exerts antioncogenic effects on Kaposi's sarcoma is therefore not resolved.

Finally, by definition, β hCG is not a pregnancy hormone, as claimed by Lunardi-Iskandar *et al.* It is at best a pregnancy marker whose serum levels are at least 100–1,000-fold less during gestation¹¹. Furthermore, a "purified native hCG preparation containing 80% β hCG and 20% α hCG" is a contradiction in terms and certainly not a biologically active holo-hormone.

We believe that hCG-like molecules

have a potential for additional functions, especially as β hCG and alternative messenger RNA splice products with open reading frames have been shown to be expressed, not only in the placenta, but also eutopically in the testis¹². Moreover, the main metabolic product of hCG, the β hCG core fragment, has a striking structural similarity to nerve growth factor and other members of the superfamily of 'cystine-knot' growth factors, suggesting a distinct biological function¹³. The suggestions of Lunardi-Iskandar *et al.* are, however, not yet proven.

Peter Berger
Stephan Dirnhofer

*Institute for Biomedical Ageing Research
of the Austrian Academy of Sciences,
A-6020 Innsbruck, Austria*

LUNARDI-ISKANDAR *ET AL.* REPLY — Rabkin *et al.* state in their analyses the interesting observation that pregnancy does not protect against Kaposi's sarcoma (KS). We agree that it is likely that factors other than hCG explain the male/female differential in this disease. In pregnancy, hCG levels peak only for a short period, and even that peak would be insufficient for long-lasting effects. Rather, we propose LH, and not hCG, as a candidate for a hormonal contribution to the sex differential in Kaposi's sarcoma¹, because the LH β -chain is 85% homologous to the β -chain of hCG^{14,15}, and because LH is higher in women than in men and much higher at some stages of the menstrual cycle¹⁶. Moreover, we find that LH has some of the same effects we reported for some hCG preparations (unpublished results).

Berger and Dirnhofer are concerned that because mice do not have hCG, but do have LH-like molecules, the inhibitory factor in mouse sera cannot be the same as in humans, namely β hCG. Mice may not have the corresponding β CG gene nor a placental hormone similar to CG, but sera of pregnant mice and women have an anti-KS factor, especially in early pregnancy. This activity is present in some preparations of hCG; it resides in the β -chain, as demonstrated using purified native β hCG¹ and also purified β hCG recombinant peptides (our unpublished data). Berger and Dirnhofer note that LH carries a related activity. Because of the homology between β hCG and β LH, we assume that if mice do not have CG, the anti-KS activity in mouse sera may well be LH or LH-like.

They also state that the reproductive biological effects of hCG are associated with the dimer. This is indeed the case; however, several workers have shown that the β -chain alone can induce signal transduction^{6,17–19} and also that β hCG competes with the dimer for receptor binding¹³, so there is good evidence that the β -chain alone contains some biological activity.

With respect to the presence of hCG

receptors, all our preliminary results indicate that the Kaposi sarcoma cells have hCG receptors (unfortunately, there was a mistake in our figure legend: the polyclonal sera were not to the ligand but to the receptor), but it is possible that the mechanism for the effect of β hCG could be independent of these. Berger and Dirnhofer note the similarity of β hCG to some growth factors²⁰, and we believe that one interpretation of our results (N. W. Isaacs, personal communication) is competition of β hCG for a growth factor needed by these tumour cells.

We disagree with Berger and Dirnhofer's contention that results with monoclonal antibodies to hCG would be more conclusive than those presented. We feel that the use of purified native β hCG and purified recombinant peptides of β hCG is sufficiently strong evidence to draw the conclusions made in our paper.

Finally, let us reiterate the novelty of our paper: Kaposi's sarcoma Y-1 cells are the first proven malignant cells obtained from HIV-associated Kaposi's sarcoma and they are killed by purified β hCG peptides. A possible additional novelty is the hypothesis of a gender susceptibility difference based on LH.

Yanto Lunardi-Iskandar
Robert A. Zeman, Victor H. Lam
Felipe Samaniego, Alain R. Thierry
Robert C. Gallo, Joseph L. Bryant

*Laboratory of Tumor Cell Biology,
National Cancer Institute and
Animal Care Unit,
National Institute of Dental Research,
National Institutes of Health,
Bethesda, Maryland 20892, USA*
Jacques M. Besnier
*Gynecology and Obstetric Medical Centre,
28 Pl. St Ferdinand, 75017 Paris, France*
Philippe Hermans
*Université Libre de Bruxelles,
St-Pierre Hôpital,
Département des Maladies Infectieuses,
1000 Bruxelles, Belgium*

Parkash Gill
*University of Southern California,
School of Medicine,
Los Angeles, California 90033, USA*

Erratum

IN the Scientific Correspondence "Non-invasive bird tagging" by D. Michard, A Ancel, J-P Gendner, J Lage, Y Le Maho, T Zorn, L Gangloff, A Schierer, K Struyf and G Wey (*Nature* 376, 649–650; 1995), the reference list was inadvertently omitted. It is given below. Also, the surname of Alfred Schierer was misspelt.

1. Bairlein, F. in *Bird Population Studies: Relevance to Conservation and Management* (eds Perrins, C. M. *et al.*) 207–229 (Oxford Univ. Press, 1991).
2. Bloesch, M. *Orn. Beob.* 77, 167–194 (1980).
3. Schierer, A. in *Encyclopédie de l'Alsace* Vol. 3, 1728–1734 (Edns Publital, Strasbourg, 1983).
4. Bairlein, F. *Vogelwarte* 31, 33–44 (1981).
5. Berthold, P., Nowak, E. & Querner, U. *J. Orn.* 133, 155–163 (1992).
6. Hall, M. R., Gwinner, E. & Bloesch, M. *J. Zool.* 211, 467–486 (1987).

1. Lunardi-Iskandar, Y. *et al. Nature* 375, 64–68 (1995).
2. Chard, T. *Hum. Reprod.* 7, 701–710 (1992).
3. Krown, S. E., Metroka, C. & Wernz, J. C. *J. clin. Oncol.* 7, 1201–1207 (1989).
4. Tapanainen, J.S. *et al. Molec. Endocr.* 7, 643–650 (1993).
5. Talmadge, K. *et al. Nature* 307, 37–40 (1984).
6. Strauss, B.L. *et al. J. biol. Chem.* 269, 4968–4973 (1994).
7. Tabarelli, M. *et al. Acta endocr.* 99, 288–294 (1995).
8. Kofler, R. *et al. Clin. exp. Immun.* 29, 326–333 (1979).
9. Dirnhofer, S. *et al. FASEB J.* 7, 1381–1385 (1993).
10. Dirnhofer, S. *et al. Immun. Today* 15, 469–474 (1994).
11. Hay, O. L. *J. clin. Endocr. Metab.* 61, 1195–1200 (1985).
12. Berger, P. *et al. FEBS Lett.* 343, 229–233 (1994).
13. Laphorn, A. J. *et al. Nature* 369, 455–461 (1994).
14. Pierce, J. G. & Parsons, T. F. *A. Rev. Biochem.* 50, 465–495 (1981).
15. Martin, M. C. *et al. in Basic and Clinical Endocrinology. The Endocrinology of Pregnancy* (ed. Greenspan, F. S.) 543–568 (Appleton & Lange, Connecticut, 1991).
16. Goldfine, A. & Monroe, S. E. in *Basic and Clinical Endocrinology. The Endocrinology of Pregnancy* (ed. Greenspan, F. S.) 442–490 (Appleton & Lange, Connecticut, 1991).
17. Hasnain, S. E. *et al. DNA Cell Biol.* 13, 275–282 (1994).
18. Yoshimura, M. *et al. Eur. J. Endocr.* 130, 92–96 (1994).
19. Ronco, A. M. *et al. Steroids* 58, 314–319 (1993).
20. Odell, W. D. *et al. in The Triggering of Ovulation in Stimulated Cycles: hCG or LH?* (ed. Emperaire, J. C.) 67–83 (Parthenon, UK, 1994).